CDKN2A-Inactivated Pancreatic Ductal Adenocarcinoma Exhibits Therapeutic Sensitivity to Paclitaxel: A Bioinformatics Study
Open accessThe DOI matches its Crossref record; 31 of the 33 references it cites were found in a registry or an index.
Abstract
The mutation of cyclin dependent kinase inhibitor 2A (CDKN2A) is frequently found in pancreatic ductal adenocarcinoma (PDAC). However, its prognostic and therapeutic roles in PDAC have not been extensively investigated yet. In this study, we mined and integrated the cancer genomics and chemogenomics data to investigate the roles of CDKN2A genetic alterations in PDAC patients’ prognosis and treatment. We found that functional CDKN2A inactivation caused by mutations and deep deletions predicted poor prognosis in PDAC patients. CDKN2A inactivation was associated with the upregulation of genes related to estrogen response, which can be overcome by CDKN2A restoration. Chemosensitivity profiling of PDAC cell lines and patient-derived organoids found that CDKN2A inactivation was associated with the increased sensitivity to paclitaxel and SN-38 (the active metabolite of irinotecan). However, only paclitaxel can mimic the effect of CDKN2A restoration, and its drug sensitivity was correlated with genes related to estrogen response. Therefore, our study suggested that CDKN2A-inactivated PDAC patients could benefit from the precision treatment with paclitaxel, whose albumin-stabilized nanoparticle formulation (nab-paclitaxel) has been approved for treating PDAC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Chemosensitivity profiles in CDKN2A-inactivated PDAC cell lines and patient-derived organoids. (a) The correlation between CDKN2A gene copy numbers and drug sensitivities in PDAC cell lines were obtained from the CTRP data via the CellMinerCDB website. Sensitive drugs correlated with low CDKN2A gene copy numbers are shown; (b) drug response data in PDAC patient-derived organoids were obtained from the supplementary materials in a previous study (reference [23]). Lower area under the curve (AUC) values indicated that the organoids were more sensitive to drug treatment.](https://figures.cochat.ai/paper-figures/e2e994cddde84bc6bcbfd21eb0dbc0a9/cdkn2a-inactivated-pancreatic-ductal-adenocarcinoma-exhibits-therapeutic-figure-3.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CDKN2A-inactivated PDAC patients exhibited increased sensitivity to paclitaxel and SN-38, suggesting these as potential therapeutic options.”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [54]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Bioinformatics analysis of TCGA’s pancreatic adenocarcinoma data underscored the importance of CDKN2A inactivation in PDAC.”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [54]
The cited source says what the claim attributes to it.
In the citing paper
“The study also proposed paclitaxel as a potential treatment for CDKN2A-inactivated PDAC patients, as it mimicked the gene expression profile associated with CDKN2A restoration [54].”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [54]
The cited source says what the claim attributes to it.
In the citing paper
“Patients with CDKN2A mutations or deep deletions experienced poorer overall survival and primary therapy outcomes.”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [54]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
NCBI GEO: archive for functional genomics data sets—update
Barrett, T., Wilhite, S. E., Ledoux, P., Evangelista, C., Kim, I. F., Tomashevsky, M., Marshall, K. A., Phillippy, K. H., Sherman, P. M., Holko, M., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1193 · Cited by 10,418
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197 · cited 2×
“0, Broad Institute, Boston, MA, USA) [17,18].”
InfluentialSpencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712 · cited 1×
“Because nab-paclitaxel plus gemcitabine has been approved for treating metastatic pancreatic cancer [10], our results may support the usage of CDKN2A genetic status as a biomarker for precision treatment of PDAC patients by nab-paclitaxel.”
ResultVisualizing and interpreting cancer genomics data via the Xena platform
Goldman, M. J., Craft, B., Hastie, M., Repečka, K., McDade, F., Kamath, A., Banerjee, A., Luo, Y., Rogers, D., Brooks, A. N., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0546-8 · Cited by 4,481 · cited 1×
“The primary therapy outcomes for these patients were obtained from the Xena Functional Genomics Explorer (accessed on 27 November 2020) [13] by selecting a cancer type and searching the phenotype “primary_therapy_outcome_success”.”
Method
Cited by
Kao, T., Wu, C.-C., Phan, N. N., Liu, Y.-H., Ta, H. D. K., Anuraga, G., Wu, Y.-F., Lee, K., Chuang, J., & Wang, C. (2021) · Aging · doi:10.18632/aging.203345 · Cited by 130
Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer
Stefanoudakis, D., Frountzas, M., Schizas, D., Michalopoulos, N. V., Drakaki, A., & Toutouzas, K. G. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46040177 · Cited by 110
Anuraga, G., Wang, W., Phan, N. N., Ton, N. T. A., Ta, H. D. K., Prayugo, F. B., Xuan, D. T. M., Ku, S., Wu, Y.-F., Andriani, V., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11111089 · Cited by 99
CDKN2A is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma
Luo, J., Wang, J., & Huang, J. (2021) · Bioscience Reports · doi:10.1042/bsr20211103 · Cited by 82
Chiao, C.-C., Liu, Y.-H., Phan, N. N., Ton, N. T. A., Ta, H. D. K., Anuraga, G., Xuan, D. T. M., Fitriani, F., Hermanto, E. M. P., Athoillah, M., et al. (2021) · Diagnostics · doi:10.3390/diagnostics11122220 · Cited by 65
Metadata
- Authors
- Lin, J.-C., Liu, T.-P., & Yang, P.-M.
- Affiliations
- Mackay Memorial Hospital (TW)
- Wan Fang Hospital (TW)
- Corresponding author
- Yang, Pei-Ming
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2020-12-12
- Volume
- 9
- Issue
- 12
- Pages
- 4019
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC7763913
- OpenAlex
- W3113368844
- Cited by
- 46
- References
- 33
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 7 · 2023: 5 · 2022: 16 · 2021: 10
- FWCI
- 2.80
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministry of Science and Technology, Taiwan (MOST109-2314-B-038-040, MOST109-2314-B-195-006)
- The health and welfare surcharge of tobacco products in Taiwan (MOHW109-TDU-B-212-134020)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- CDKN2A, pancreatic ductal adenocarcinoma, paclitaxel, chemosensitivity, prognostic factors, SN-38, irinotecan, patient-derived organoids, nab-paclitaxel, CDKN2A mutation, CDKN2A deletion
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CDKN2A-Inactivated Pancreatic Ductal Adenocarcinoma Exhibits Therapeutic Sensitivity to Paclitaxel: A Bioinformatics Study. https://app.cochat.ai/papers/10.3390/jcm9124019
- The paper
- Lin, J.-C., Liu, T.-P., & Yang, P.-M. (2020). CDKN2A-Inactivated Pancreatic Ductal Adenocarcinoma Exhibits Therapeutic Sensitivity to Paclitaxel: A Bioinformatics Study. Journal of Clinical Medicine. https://doi.org/10.3390/jcm9124019
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.